Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Price Gaps between Original Drugs and Generics too Large: Mr Mukai of MOF
June 25, 2007
- REGULATORY NEWS IN BRIEF
June 25, 2007
- OPINION：Be the First to Know
June 25, 2007
- Smoking Rate Drops Below 40% in Men for First Time
June 25, 2007
- 43rd ASCO Annual Meeting in Chicago(1)
June 25, 2007
- Eisai Licenses Kissei's Glufast in ASEAN Countries
June 25, 2007
- 43rd ASCO Annual Meeting in Chicago(2)
June 25, 2007
- REGULATORY NEWS IN BRIEF
June 18, 2007
- R&D NEWS IN BRIEF
June 18, 2007
- Takeda Looks for Alliance, Acquisition Opportunities: President Hasegawa
June 18, 2007
- Five Medical Devices Recommended for Priority Review
June 18, 2007
- SURVEY／Metabolic Syndrome Affects 19 Mil. Japanese
June 18, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 18, 2007
- Bulk Buying by Sum Value Should Be Eliminated: FJPWA President
June 18, 2007
- 40,000-50,000 Registered Drug Salespersons Needed at First: JACDS SG
June 18, 2007
- OPIR Proposes Actual Purchase Price Reimbursement System
June 18, 2007
- Mr Matsumoto Reelected JACDS President
June 18, 2007
- Market for Ethical Drugs Declined 0.5% in FY2006: IMS
June 18, 2007
- Taisho to Start Ads Using Clinical Data
June 18, 2007
- Nikko, Daiwa Downgrade Chugai’s Share due to Avastin’s Lower-Than-Expected NHI Prices
June 18, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…